Portal Instrument's CEO, Dr. Patrick Anquetil, shares insights on reducing healthcare waste through reusable autoinjectors in a compelling OnDrug Delivery interview, "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors."
We are thrilled to highlight a recent interview in OnDrug Delivery (Issue 171) featuring our CEO, Dr. Patrick Anquetil. Titled "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors," the article tackles the significant environmental challenges and extensive waste generated by single-use autoinjectors in the self-injection market. Dr. Anquetil presents a compelling case for pivoting towards reusable electromechanical autoinjectors as a more sustainable and potentially cost-effective path forward. The discussion showcases Portal Instruments' solution, PRIME Nexus – a flexible, needle-based reusable platform – and explores broader insights into reducing waste, the benefits of connected reusable devices, and why sustainable innovation should ultimately lead to lower healthcare costs. The full article can be read in OnDrug Delivery.
September 28, 2021 - Cambridge, MA Portal Instruments, developer of the PRIME needle-free drug delivery platform, announced that a new clinical study demonstrating patient preference for PRIME needle-free injections was published this month in the journal Drug Delivery.
September 8, 2020 - Portal Instruments was founded with the goal to completely disrupt how injections are given and to replace the needle and syringe with a modern, convenient and safe technology. Our Vision is a Needle-Free World.
March 27th, 2020 Portal’s mission is to improve the experience for patients on life-changing therapies and that mission remains in the forefront of our minds as we, like everyone else, navigate these unchartered waters with the COVID-19 pandemic.
Please fill out the details below and we will get back to you shortly.